Multicentric open-label study of the efficacy and tolerability of citicoline in the treatment of acute cerebral infarction

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 5, 1997, Pages 309-316

  Bruhwyler, Jacques ^a   Van Dorpe, Jan ^a   Géczy, Joseph ^a  

^a Therabel Pharma Belgium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CITICOLINE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRAIN INFARCTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HICCUP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RATING SCALE; SEIZURE; STROKE; SYMPTOM; VERTIGO;

EID: 0030986027     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80028-8     Document Type: Article

References (17)

1. Sandercock PAG, Celani MG, Ricci S. The likely public health impact in Europe of simple treatments for acute ischaemic stroke. Cerebrovasc Dis. 1992;2:236. Abstract.
2. Cambier J, Masson M, Dehen H, eds. Pathologie vasculaire cérébrale. In: Abrégés de Neurologie. Paris: Ed Masson; 1994:373-422.
3. Dorman PJ, Counsell CE, Sandercock PAG. Recently developed neuroprotective therapies for acute stroke. CNS Drugs. 1996;5:457-474.
4. Counsell C, Sandercock PAG. The management of patients with acute ischaemic stroke. Curr Med Lit: Geriatry. 1995;7:99-110.
5. D'Orlando KJ, Sandage BW. Citicoline (CDP-choline): Mechanisms of action and effects in ischemic brain injury. Neurol Res. 1995;17:281-284.
6. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995;56:637-660.
7. Caamano J, Gomez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1994;16:211-218.
8. Cacabelos R, Caamano J, Gomez MJ, et al. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann New York Acad Sci. 1996;777:399-403.
9. 15O-PET study. Rinsho Shinkeigaku. 1994;34:877-881.
10. Rossi M, Zanardi M. An open study on the clinical efficacy of citicoline in patients with chronic cerebral vasculopathy. Clin Ther. 1993;142:141-144.
11. Clandinin MT, Suh M, Hargreaves K. Impact of dietary fatty acid balance on membrane structure and function of neuronal tissues. Adv Exp Med Biol. 1992;318:197-210.
12. Lopez-Coviella I, Agut J, Savci V, et al. Evidence that 5′-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. J Neurochem. 1995;65:889-894.
13. Agut J, Lopez-Coviella I, Ortiz JA, Wurtman RJ. Oral cytidine 5′-diphosphate choline administration to rats increases brain phospholipid levels. Ann New York Acad Sci. 1993;695:318-320.
14. Tazaki Y, Sakai F, Otomo E. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke. 1988;19:211-216.
15. Guillen F, Buendia C, Herrera J. CDP-choline in the treatment of acute ischaemic stroke. J Neurol. 1995;242(Suppl 2):S76. Abstract.
16. Citicoline improves outcomes in stroke. Marketletter. February 26, 1996:19.
17. Franco-Maside A, Caamano J, Gomez MJ, Cacabelos R. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1994;16:597-607.